N
NYXH
NYXOAH S A
1.600
-0.040-2.44%After Hours: 1.600 0.000 0.00%19:30 08/21 EDT
OPEN/PREV CLOSE1.640/1.640
TODAY RANGE1.585-1.650
VOL164.07K
MARKET CAP160.12M
52 WEEK RANGE1.260-6.87
AVG VOL (3M)330.81K
% TURNOVER0.16%
TURNOVER--
P/E (TTM)-0.6476
% RANGE3.96%
EPS(TTM)-2.4706
P/E(FORWARD)-1.1289
P/B1.687
BVPS0.9487
DIVIDEND--
P/S5.85
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP88.31M
SHARES OUTSTANDING100.07M
NEXT EARNINGS03/11-03/16
FREE FLOAT55.19M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Benzinga·08/06 16:43
Piper Sandler Reiterates Overweight on Nyxoah, Lowers Price Target to $6
TipRanks·08/06 13:38
Nyxoah price target lowered to $2.31 from $2.86 at Baird
TipRanks·08/06 13:06
Nyxoah price target lowered to $6 from $7 at Piper Sandler
TipRanks·08/05 20:33
Nyxoah Q2 2026 Results Show Rapid U.S. Growth for Genio Sleep Apnea Therapy
NASDAQ·08/05 18:00
INSP Raises 2026 Outlook as Reimbursement Headwinds Start to Ease
TipRanks·07/09 20:58
Nyxoah Updates Major Shareholdings as Investor Stakes Shift
TipRanks·07/09 16:05
Nyxoah (NYXH) Receives a Buy from Piper Sandler
TipRanks·07/09 10:20
Nyxoah price target lowered to $2.85 from $4 at Baird
TipRanks·07/08 13:20
Wall Street Analysts Are Neutral on Top Healthcare Picks
TipRanks·07/08 01:32
Nyxoah Rides U.S. Momentum and CMS Boost in Strong Q2 Preliminary Results
Seeking Alpha·07/07 20:19
Nyxoah reports Q2 2026 preliminary revenue of €7.7M
TipRanks·07/07 20:15
Nyxoah sees Q2 revenue EUR 7.7M
TipRanks·07/07 20:15
Nyxoah backs FY26 revenue view EUR 36M-EUR 40M